APA (7th ed.) Citation

Gjermeni, D., Alexander, K. M., Januzzi, J. L., & Mahaffey, K. W. (2026). Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update? Cardiology & Therapy, 15(3), 265. https://doi.org/10.1007/s40119-026-00462-8

Chicago Style (17th ed.) Citation

Gjermeni, Diona, Kevin M. Alexander, James L. Januzzi, and Kenneth W. Mahaffey. "Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?" Cardiology & Therapy 15, no. 3 (2026): 265. https://doi.org/10.1007/s40119-026-00462-8.

MLA (9th ed.) Citation

Gjermeni, Diona, et al. "Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?" Cardiology & Therapy, vol. 15, no. 3, 2026, p. 265, https://doi.org/10.1007/s40119-026-00462-8.